Clinical Trials Logo
  1. Home
  2. Overall Survival
  3. NCT05392257

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Overall Survival Clinical Trial

Official title:
Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Clinical Trial Summary

This clinical trial is an investigator-initiated multicenter, open, prospective clinical study in order to explore the efficacy and safety of rituximab plus zanubrutinib and lenalidomide in relapsed and refractory diffuse large B cell lymphoma.

Clinical Trial Description

Subjects are patients withRelapsed and refractory Diffuse Large B cell lymphoma (DLBCL). All included patients will be treated with rituximab plus zanubrutinib and lenalidomide. In the induction stage, patients will receive 375 mg/m2 rituximab Day 1 of Cycles 1-6, twice-daily 160 mg zanubrutinib and 25 mg lenalidomide Days 1-21 of each 28-day cycle. In the maintenance treatment period, patients will receive 375 mg/m2 rituximab every 2 months, twice-daily 160 mg zanubrutinib and 10 mg lenalidomide Days 1-21 of each 28-day cycle. Imaging evaluation will take every two cycles to determine the best therapeutic effect, PD patients will exit from the clinical trial. The comprehensive therapeutic evaluating will take after 4 cycles. Peripheral blood stem cells can be collected from young patients with PR or CR. If patients' condition is suitable after 6 cycles of induction therapies, autologous hematopoietic stem cell transplantation can be chosed for patients with PR or CR and exit from the trail.Primary study endpoint is objective response rate (ORR) at the end of 6 cycles of induction therapy. Secondary study endpoints include progression-free survival time (PFS), overall survival (OS) and adverse reaction events (TEAS). After sample size calculation, we plan to enroll 72 relapsed and refractory diffuse large B cell lymphoma patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05392257
Study type Interventional
Source Qingdao Central Hospital
Contact
Status Recruiting
Phase Phase 2
Start date May 1, 2022
Completion date May 1, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT04111926 - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery Phase 4
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Recruiting NCT03910140 - TILA-TACE in Treatment of Hepatocellular Carcinoma N/A
Completed NCT03923400 - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn NCT02201381 - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Phase 3
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Active, not recruiting NCT04245644 - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting NCT04245410 - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed NCT02980185 - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer N/A
Recruiting NCT03967457 - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting NCT04050787 - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Completed NCT03726021 - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT02942238 - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC) N/A
Not yet recruiting NCT01236989 - Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC N/A
Recruiting NCT05218629 - Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer Phase 2